Click here to view online. Add this email to your safelist.
Datopotamab deruxtecan and Enhertu show promising early clinical activity in patients with advanced non-small cell lung cancer
29 January 2021
New data from AstraZeneca and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo)’s datopotamab deruxtecan (Dato-DXd; DS-1062) and Enhertu (trastuzumab deruxtecan) showed encouraging results from both antibody drug conjugates (ADCs) in patients with advanced or metastatic non-small cell lung cancer (NSCLC). The data were presented today in two oral presentations during the World Conference on Lung Cancer (WCLC), hosted by the International Association for the Study of Lung Cancer (IASLC).
|
|||||
|
|||||
|
For more information please visit astrazeneca.com. If you would like to unsubscribe please click here. |
